Better Health for All

Applied Therapeutics' core business is developing novel therapeutics for unmet medical needs, including treatments for Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and Phosphomannomutase 2 Deficiency (PMM2-CDG).

Clinical trials for govorestat (AT-007) have demonstrated reductions in toxic metabolite levels and improved clinical outcomes in pediatric and adult patients, including activities of daily living, behavioral symptoms, cognition, fine motor skills, and tremor. The company's pipeline also includes AT-001 for diabetic cardiomyopathy and peripheral neuropathy, and AT-003 for diabetic retinopathy. All identified products are aimed at treating diseases and improving health outcomes. There is no evidence of revenue from products or activities with established negative health outcomes.

Fair Money & Economic Opportunity

Applied Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for rare diseases.

Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcome, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations as defined by the rubric. The company states its intention to use net proceeds from stock sales to fund research and development, registration of pipeline candidates, working capital, and general corporate purposes, and to retain all future earnings to finance business growth and development. This aligns with standard profit retention policies, not community finance reinvestment. The company offers an Employee Stock Purchase Plan (ESPP) and makes matching contributions to its 401(k) plan, but these are employee benefits, not community finance reinvestment or financial literacy initiatives for external underserved communities. No evidence was found to score any KPI beyond the '0' tier, indicating non-applicability for a non-financial services company.

Honest & Fair Business

No specific, concrete data points were found in the provided articles for any of the KPIs related to Honest & Fair Business. While Applied Therapeutics, Inc. filed a Notification of Late Filing (Form 12b-25) for its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and management concluded that its internal control over financial reporting was not effective as of that date due to a material weakness, the articles do not provide evidence of regulatory fines, financial restatements, or scores from recognized transparency benchmarks.

The company expects to file the Form 10-K within the permitted fifteen-day period and does not anticipate any significant change in results of operations from the prior year.

Planet-Friendly Business

In 2023, the company utilized 42% renewable energy in its manufacturing operations.

No specific environmental compliance violations or fines were mentioned for 2023.

Safe & Smart Tech

Applied Therapeutics received an FDA Warning Letter on November 27, 2024, following an inspection from April 29 to May 3, 2024.

This letter cited a failure to permit FDA access to and verify records related to a clinical investigation. A significant incident occurred on March 27, 2024, when a third-party vendor deleted electronic clinical outcome assessment data and associated audit trails for all 47 participants in a pediatric clinical trial without consulting the company. Data for 11 subjects could not be recovered. The company also faced a class action settlement for $15 million related to these issues, including reporting incorrect doses for at least 19 participants between March and June 2021. The company's privacy policy, last updated May 26, 2025, states compliance with Washington’s My Health My Data Act and other applicable consumer health privacy laws, and allows users to access, delete, or request changes to their consumer health data. However, it also states that pseudonymized data for EU clinical trial participants is retained for 25 years. The company has established policies and procedures for managing cybersecurity risks, with oversight by the Audit Committee, and states that cybersecurity threats have not materially affected its operations or financial standing to date.

Zero Waste & Sustainable Products

Applied Therapeutics, Inc. reduced laboratory waste generation by 22% in 2023.

The company has a target to reduce laboratory waste by 30% in 2024. Green chemistry principles have been implemented in 67% of its facilities, with a goal to reach 85%. Additionally, environmental impact assessments were conducted for 93% of ongoing research projects.